Bruce W. S. Robinson

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

David L. Gibbs, Benjamin E. Gross, Zachary J. Heins, 2018, Cancer discovery.

Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma

S. Skates, A. Musk, J. Creaney, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Computational immunogenomic approaches to predict response to cancer immunotherapies

F. Newell, J. Creaney, V. Addala, 2023, Nature reviews. Clinical oncology.

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma

M. Millward, M. Platten, J. Creaney, 2008, British Journal of Cancer.

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

B. Turlach, A. Musk, M. Millward, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.

J. Pearson, R. Holt, N. Waddell, 2018, Lung cancer.

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.

A. Musk, J. Upham, G. van Hazel, 1993, Australian and New Zealand journal of medicine.